Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Duragesic — SUBLIMAZE PRESERVATIVE FREE
Application NDA016619 (NDA)
Duragesic — FENTANYL CITRATE
Application NDA019115 (NDA)
Duragesic — DURAGESIC-100
Application NDA019813 (NDA)
Duragesic — FENTANYL
Application NDA020195 (NDA)
Duragesic — ACTIQ
Application NDA020747 (NDA)
Gabitril — GABITRIL
Application NDA020646 (NDA)
Trisenox — TRISENOX
Application NDA021248 (NDA)
Duragesic — FENTORA
Application NDA021947 (NDA)
Duragesic — IONSYS
Application NDA021338 (NDA)
Duragesic — ONSOLIS
Application NDA022266 (NDA)
Duragesic — LAZANDA
Application NDA022569 (NDA)
Duragesic — ABSTRAL
Application NDA022510 (NDA)
GRANIX — GRANIX
Application BLA125294 (BLA)
Duragesic — SUBSYS
Application NDA202788 (NDA)
TRUXIMA — TRUXIMA
Application BLA761088 (BLA)
Duragesic — FENTANYL CITRATE
Application NDA215870 (NDA)
Duragesic — FENTANYL CITRATE
Application NDA019101 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)